Loading stock data…
FTRE
$12.18+0.68 (+5.91%)
Market ClosedLast close May 1
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fortrea Holdings Inc. in the Healthcare sector is trading at $12.18. The stock is currently 35% below its 52-week high of $18.67, remaining 9.1% above its 200-day moving average. Technical signals show overbought RSI of 77 and bullish MACD crossover, explaining why FTRE maintains its current momentum and trend strength. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 77) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$12.18
Potential Upside
5%
Whystock Fair Value$12.79
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$12.66+4.0%
Range$8.00 – $16.00
Fundamentals
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as cl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$981.75M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-182.24%
Volume
Today's trading volume
1.15M
Recent News
3 Small-Cap Stocks with Questionable Fundamentals
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 of Wall Street’s Favorite Stocks to Consider Right Now and 1 We Question
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Evercore Adjusts Fortrea Holdings Inc. (FTRE) Valuation Following Updated Near-Term Assumptions
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Fortrea Holdings Inc. is among the best biotech stocks. TheFly reported on April that Evercore ISI cut FTRE price target to $14 from $25 while keeping an Outperform rating. The change was part of a broader Q1 healthcare technology and […]